Abstract:Immunization of primates or humans with human immunodeficiency virus type 1 (HIV-1) glycoproteins usually elicited moderate immune responses to the principal neutralizing determinant (PND) located within the V3 hypervariable loop of gp120. Since an antibody response to the PND appears to be protective, experiments were carried out to determine the responsiveness of chimpanzees to immunization with synthetic peptides corresponding to the full-length V3 loop. Seven chimpanzees (4 preimmunized with gp160, 2 preimmunized with HIV-1 antigens unrelated to gp160, and 1 unimmunized) were vaccinated with a mixture of full-length V3 loop peptides from 21 distinct HIV-1 isolates (clones) either in unconjugated form or linked to carrier proteins from HIV-1 nef and gag P18, respectively. Six chimpanzees developed high levels of antibodies to the peptides (dilution endpoints 1:> 25,000), and 5 had high levels of antibodies to gp120 from HIV-1IIIB (endpoint titers 1: > 500,000). Chimpanzees immunized with peptide-carrier conjugates (4) had antibodies to the carrier proteins nef and gag P18, respectively (endpoint titers 1: greater-than-or-equal-to 35,000). Virus-neutralizing (VN) antibodies were detected in sera of 5 of 7 chimpanzees, but were present at titers of 1: greater-than-or-equal-to 400 only in sera of 2 chimpanzees. One of these was challenged with HIV-1 and was protected against infection, as reported elsewhere. The antibodies were primarily specific for the HIV-1 isolate used for primary immunization before boosting with peptides. The relatively low dilution endpoints of VN antibodies as compared with endpoints determined by site-specific immunoassays probably can be ascribed to imperfect mimicry of conformational epitopes by synthetic peptides. Nevertheless, sequential or simultaneous immunization with recombinant envelope glycoproteins of HIV-1 and selected synthetic peptides offers an approach for eliciting protective immunity against HIV-1.

Protective effect of a synthetic peptide comprising the complete pres2 region of the hepatitis b virus surface protein

Longitudinal Mapping of Hepatitis B Vaccine-Induced B-cell Linear Epitopes in Healthy Individuals

Immune Response Against Hepatitis B Virus Induced by HBsAg Recombinant Adenovirus-Transduced Dendritic Cells in BALB/c Mice

A Bacterially Expressed Peptide Prevents Experimental Infection of Primates by the Hepatitis E Virus.

A Synthetic Peptide Elicits Antibody Reactive with the Native Duck Hepatitis B Virus Pre-S Protein

An Anti-Pres2 Antibody Protects Human Hepatocytes From Hepatitis B Virus Infection

A Virus-Like Particle of the Hepatitis B Virus Pres Antigen Elicits Robust Neutralizing Antibodies and T Cell Responses in Mice.

Vaccines Targeting PreS1 Domain Overcome Immune Tolerance in HBV Carrier Mice

High immunogenicity of a hydrophilic component of the hepatitis B virus preS1 sequence exposed on the surface of three virus-like particle carriers

Production of antibody to individual polypeptides derived from purified hepatitis B surface antigen

In vivo activity of a mixture of two human monoclonal antibodies (anti-HBs) in a chronic hepatitis B virus carrier chimpanzee.

Secretory Expression of the Fusion Protein Composed of Human Il-2 and Pres Antigen of Hepatitis B Virus in Mammalian Cells

A bi-functional hepatitis B virus core antigen (HBcAg) chimera activates HBcAg-specific T cells and preS1-specific antibodies.

Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice

Neutralization Effects of Antibody Elicited by Chimeric HBV S Antigen Viral-Like Particles Presenting HCV Neutralization Epitopes.

Selective synthesis and secretion of particles composed of the hepatitis B virus middle surface protein directed by a recombinant vaccinia virus: induction of antibodies to pre-S and S epitopes

Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance

A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice

Antibody Responses of Chimpanzees Immunized with Synthetic Peptides Corresponding to Full-Length V3 Hypervariable Loops of HIV-1 Envelope Glycoproteins.

Efficient Inhibition of Hepatitis B Virus Infection by a Pres1-Binding Peptide

Generation of Hepatitis B Virus PreS2-S Antigen in Hansenula Polymorpha